Phase I/II – First Administration

454 trials 191 recruiting

Filter these 454 trials by condition, country, sponsor and more.

Open in Search →

A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid Tumors Ended

2023-503484-42-00 Advanced, metastatic, solid malignancy 2023-10-19
Phase I/II study of QEL-001 in A2-mismatch liver transplant patients Ended

2024-516193-30-01 Prevention of liver transplant rejection 2023-10-02
A Phase 1/2a Study of Safety, Pharmacokinetics and Neutralizing Activity of SPK002 as pre-exposure prophylaxis of COVID-19 in healthy volunt… Ended

2023-505279-62-00 Immunocompromised individuals (phase 2a) 2023-07-10
A Safety, Tolerability, and Efficacy Study of VX-264 in Subjects With Type 1 Diabetes Ended

2024-515583-32-00 Type 1 Diabetes Mellitus 2023-07-06
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD). Ended

2022-501250-12-01 Inherited retinal dystrophies 2023-03-17
A study of MP0533 in patients with blood cancer. Ended

2023-505259-39-00 Acute Myeloid Leukemia (AML) 2023-03-02
Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Ended

2023-510351-31-00 Duchenne muscular dystrophy 2023-01-06
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine… Ended

2023-506818-45-00 Solid tumors that have a high incidence of Homologous R 2022-12-13
A trial to determine the safety and tolerability of transplanted stem cellderived dopamine neurons to the brains of individuals with Parkins… Ended

2024-511237-35-00 Parkinson's disease 2022-11-30
A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid Tumors Ended

2024-512120-11-00 Part 1B &1C HR-positive/HER2-negative breast cancer 2022-08-31
ATA-100 gene therapy trial in patients with limb-girdle muscular dystrophy Ended

2023-506677-36-00 FKRP-related limb-girdle muscular dystrophy (LGMD R9) 2022-07-18
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Ended

2023-510353-42-00 Myotonic Dystrophy Type 1 2022-02-21
Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended

2024-510655-36-00 Advanced Malignancies Associated with EphA2 Expression 2022-02-01
Safety and Efficacy of AMT-130 in European Adults with Early Manifest Huntington Disease Ended

2024-511766-37-00 Huntington’s Disease 2021-10-07
A trial to learn how safe rilvegostomig (AZD2936) is, how it moves throughout the body over time, and how well it works in adults with advan… Ended

2023-508262-15-00 Advanced Non-small Cell Lung Cancer, Metastatic Non-sma 2021-09-09
Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended

2022-502856-29-00 Advanced Solid Tumors 2021-07-27
Actuate 1801: Elraglusib (9-ING-41) is an investigational study drug give alone or in combination with other chemotherapies, for the potenti… Ended

2024-518409-16-00 Refractory Hematologic Malignancies or Solid Tumors 2021-04-14
Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies. Ended

2023-509781-37-00 Nectin-4 Expressing Advanced Malignancies. 2021-04-12
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexande… Ended

2024-510603-11-00 Alexander Disease 2021-04-08
CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL Ended

2024-519174-39-00 Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia 2021-02-15
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 2020-10-30
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced C… Ended

2024-517536-22-00 Unresectable or metastatic cutaneous squamous cell carc 2020-09-22
Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended

2023-507062-34-00 High-Risk large B-Cell lymphoma 2020-08-07
A first-in-human clinical study to assess feasibility, safety and antitumor activity of genetically modified T-cells in multiple myeloma Ended

2024-512643-23-00 Multiple myeloma 2020-06-22